358971-49-0

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 261924-66-7 1-[bis(4-chlorophenyl)methyl]-azetidin-3-ol 
• 90-98-2 4,4'-Dichlorobenzophenone 
• 1161418-95-6 3-{[bis(4-chlorophenyl)methylene]amino}propane-1,2-diol 
• 1161418-96-7 3-{[bis(4-chlorophenyl)methyl]amino}propane-1,2-diol 

Downstream Products

• 358970-97-5 Drinabant 
• 358971-54-7 1-[bis(4-chlorophenyl)methyl]-azetidin-3-ylamine 
• 358971-26-3 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(1,1-dioxo-1H-1λ6-benzo[d]isothiazol-3-yl)amine 
• 358971-20-7 N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulphonamide 
• 1161500-82-8 3-({1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}(methanesulphonyl)amino)-5-fluorobenzoic acid ethyl ester 

Relevant academic research and scientific papers

METHOD FOR PREPARING AZETIDINE DERIVATIVES

This invention discloses and claims an industrial method for the production of azetidine derivatives, such as, N-(1-benzhydrylazetidin-3-yl)-N-phenylmethylsulphonamide.

METHOD AND INTERMEDIATES FOR THE PREPARATION OF DERIVATIVES OF N (1-BENZHYDRYLAZETIDIN-3-YL)-N-PHENYLMETHYLSULFONAMIDE

The invention relates to a novel method for the synthesis of N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}-N-(3,5-difluorophenyl)methylsulfonamide.

Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease

The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their us